Drug Pricing & Pharmacy
Expert articles and analysis related to drug pricing & pharmacy.
AI Summary — Last 7 Days
CMS is extending the manufacturer application deadline for the Medicaid GENEROUS Model, signaling stronger-than-expected pharma interest in outcomes- and value-linked drug pricing under the Trump administration and creating near-term opportunities for states to test alternative payment arrangements for high-cost therapies (CMS extends GENEROUS model deadline). At the same time, the proposed drug interoperability and prior authorization rule is pushing pharmacy benefit management toward more standardized electronic data exchange, reinforcing a broader shift in which specialty pharmacy, advanced therapy payment models, and health-system pharmacy programs are becoming core infrastructure for VBC performance, medication adherence, and total-cost accountability (drug interoperability and prior authorization proposed rule summary).
Related Articles
Are drug prices value-based?
One of the central tensions in pharmaceutical policy is the gap between what a drug is worth and what it actually costs. In theory, a drug’s price should reflect its value — its ability to improve hea...
CMS extends GENEROUS model deadline for pharma and states
The Centers for Medicare and Medicaid Services is extending the application deadline for drug manufacturers to apply to the GENErating cost Reductions fOr U.S. Medicaid Model. CMS said it made the dec...
Humana’s CenterWell fleshes out partnership with Mark Cuban’s Cost Plus Drugs
Humana’s CenterWell fleshes out partnership with Mark Cuban’s Cost Plus Drugs Becker's Hospital Review
Hospitals, insurers clash on 340B rebate costs
Hospitals and insurers both urged federal regulators to ignore the cost projections of the other side in their comments on a coming redux of a 340B rebate model. The comments came in response to a req...
Will Tennessee’s PBM Bill Face the Same Fate as Arkansas’ Law?
Will Tennessee’s PBM Bill Face the Same Fate as Arkansas’ Law? MedCity News
Federal judge permanently blocks North Dakota 340B drug law
Federal judge permanently blocks North Dakota 340B drug law Becker's Hospital Review
PBMs lean on private label biosimilars to cut costs, boost profit
PBMs lean on private label biosimilars to cut costs, boost profit Modern Healthcare
What 3 Rounds of IRA Negotiations Have Taught Manufacturers About Readiness
Humana teams with Mark Cuban's Cost-Plus Drug Company
Humana's CenterWell Pharmacy has teamed with the Mark Cuban Cost Plus Drug Co. on a new employer-based program.Cost Plus Drugs has selected CenterWell Pharmacy as a pharmacy partner. Its digital pharm...
HRSA wants a 340B rebate pilot. Here’s what the industry thinks
HRSA wants a 340B rebate pilot. Here’s what the industry thinks Modern Healthcare